AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
ABBVie today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO® in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. The positive CHMP opinion is a scientific recommendation for marketing authorization to the … ABBVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VENCLYXTO...
Source: investingnews.com